Brain Cancer Clinical Trials in Pennsylvania

Showing 41-60 of 175 trials

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

NCT04869449

This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

GlioblastomaGlioblastoma MultiformeGlioblastoma Multiforme of Brain+1 more

Milton S. Hershey Medical Center1 participantsStarted May 2022

Hershey, Pennsylvania, United States

Active Not RecruitingPhase 240 miles

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more

National Cancer Institute (NCI)5 participantsStarted Oct 2020

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +169 more locations

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Brain Cancer Trials in Other Cities

Neoadjuvant Chemoradiation for Resectable Glioblastoma

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Neuronal and Network Mechanisms of Electrocortical Stimulation

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

AB154 Combined With AB122 for Recurrent Glioblastoma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

Other Conditions in Pennsylvania